Overview
Industry leading TCR pipeline targeting solid tumors
Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.
SPEAR® T-cell therapies targeting MAGE-A4, and AFP are progressing through clinical studies in multiple solid tumors. The clinical studies for SPEAR® T-cell therapies targeting MAGE-A10 have been closed.
Our Pipeline
Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.
Low-radiation Sub-study (ADP-A2M4)
This is a Phase 1, single-center sub-study to characterize safety and tolerability and assess anti-tumor activity of low dose radiation in combination with ADP-A2M4 across multiple tumor types. Up to 10 patients will be treated at MD Anderson Cancer Center. This is a sub-study of the ADP-A2M4 Phase 1 trial.
View Clinical TrialsSPEARHEAD-2 (afamitresgene autoleucel in combination with pembrolizumab)
This is a Phase 2, single arm clinical trial to investigate the efficacy and safety of afamitresgene autoleucel in combination with pembrolizumab in HLA-A*02 positive patients with recurrent or metastatic head and neck cancer expressing MAGE-A4.
View Clinical TrialsSURPASS (ADP-A2M4CD8) Phase 1 clinical trial
This is a Phase 1, open-label, dose escalation clinical trial to evaluate the safety and anti-tumor activity of next-generation ADP-A2M4CD8 SPEAR T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced urothelial cancer, esophageal cancers, gastroesophageal junction cancer, gastric cancer, non-small cell lung cancer (NSCLC) or head and neck cancer expressing MAGE-A4.
View Clinical TrialsADP-A2AFP Phase 1 clinical trial
This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2AFP therapeutic candidate. The ongoing trial will include patients who have advanced hepatocellular carcinoma (liver cancer), which has grown or returned after being treated, and who are HLA-A*02 positive and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein. Patients who did not tolerate or refused other therapies may also participate. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2AFP SPEAR T-cell therapy.
View Clinical TrialsADP-A2M4 Phase 1 clinical trial
This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2M4 therapeutic candidate (now called afamitresgene autoleucel or afami-cel) in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial cancer, head and neck cancers, ovarian cancer, non-small cell lung cancer (NSCLC), esophageal cancers, synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), and gastric cancers expressing MAGE-A4. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2M4. Further details are available via the link below.
Please note that this trial is not enrolling patients with the exception of the low-radiation sub-study.
View Clinical TrialsSPEARHEAD-1 (afamitresgene autoleucel)
This is a Phase 2, open-label, single arm clinical trial to evaluate the anti-tumor activity of afamitresgene autoleucel in patients who are HLA-A*02 positive and have inoperable locally advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) expressing MAGE-A4.
View Clinical Trials
